Section 69511.4 - Carpets and Rugs Containing Perfluoroalkyl or Polyfluoroalkyl Substances(a)(1) "Carpets and rugs containing perfluoroalkyl or polyfluoroalkyl substances," means any consumer product made from natural or synthetic fabric intended to be used as a floor covering inside commercial or residential buildings that contains any member of the class of perfluoroalkyl and polyfluoroalkyl substances (PFASs). This includes carpeted door mats.(2) Notwithstanding subsection (a)(1), "carpets and rugs containing perfluoroalkyl or polyfluoroalkyl substances" does not include: (A) Carpets and rugs intended solely for outdoor use;(B) Carpets and rugs intended solely for use inside airplanes, trains, ships, automobiles, light duty trucks, vans, buses, or any other vehicles, as well as aftermarket or replacement parts marketed solely for use in vehicles;(C) Resilient floor coverings;(E) Wall hangings and coverings;(G) Camping sleeping mats.(b) Candidate Chemical. For purposes of this chapter, the following Candidate Chemical is identified as the basis for the product defined in subsection (a) being listed as a Priority Product:(1) Perfluoroalkyl and polyfluoroalkyl substances (PFASs), a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom, as defined by the California Environmental Contaminant Biomonitoring Program in "Biomonitoring California Priority Chemicals," February 2019 (incorporated by reference, see section 66260.11 of this division).(c) Hazard traits associated with PFASs include one or more of the following: (2) Cardiovascular toxicity;(3) Developmental toxicity;(9) Reproductive toxicity;(10) Environmental persistence;(12) Mobility in environmental media; and(13) Lactational and transplacental transfer.(d) Toxicological and environmental endpoints associated with exposure to certain PFASs include: (1) Kidney and testicular cancers in humans;(2) Increased serum cholesterol and increased risk of heart disease in humans;(3) Decreased birth weight in humans; reduced ossification and accelerated puberty in male mice; decreased hatching success in bird eggs; delayed metamorphosis in frogs; tail deformation, uninflated swim bladders, and increased occurrence of malformations in zebrafish;(4) Thyroid disease and obesity in humans; pubertal disorders in mice;(5) Increased liver weight and liver tumors in mice;(6) Decreased effectiveness of vaccines, ulcerative colitis, and increased risk of respiratory tract infections in humans;(7) Renal disease in humans;(8) Delayed pupil response and retina degeneration in rats; and(9) Pregnancy-induced hypertension and decreased fertility in humans; delayed eye opening and delayed puberty in mice; decreased hatching success in birds.(e) For the purposes of this chapter, the Candidate Chemical identified in subsection (b) is designated as the Chemical of Concern for the product defined in subsection (a).(f) The Preliminary Alternatives Analysis Report for this Priority Product shall be submitted within 180 days after the effective date of this regulation.Cal. Code Regs. Tit. 22, § 69511.4
1. New section filed 6-22-2021; operative 7-1-2021 pursuant to Government Code section 11343.4(b)(3) (Register 2021, No. 26). Note: Authority cited: Sections 25252, 25253 and 58012, Health and Safety Code. Reference: Sections 25252 and 25253, Health and Safety Code.
1. New section filed 6-22-2021; operative 7/1/2021 pursuant to Government Code section 11343.4(b)(3) (Register 2021, No. 26).